Clinical trial
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
NCT00201123 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00201123 |
|---|---|
| Title | Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs |
| Official title | Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tuberculosis, AIDS-related Complex |
| Intervention type | Drug, Other |
| Interventions | Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo |
| Enrollment | 89 |
| Start date | Apr 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 16, 2016 |
| Countries | South Africa, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: